Vaxxas, a clinical-stage biotech commercializing a novel vaccination platform, has appointed Doug Cubbin as Chief Financial Officer.
Cubbin joins Vaxxas as the Brisbane, Australia headquartered company experiences ‘significant growth and advances’ toward commercialization of its high-density microarray patch (HD-MAP) vaccine delivery technology: most recently with the completion of a financing round raising US $23m and the Phase 1 trial of its COVID-19 patch. The company, which currently employs over 110 people, will move into a state-of-the-art manufacturing facility being built by the Queensland Government in Brisbane in early 2023.
Cubbin has more than 30 years’ experience in finance, M&A, and business development. Most recently, he was the Group Chief Financial Officer at Telix Pharmaceuticals Limited, a global biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic products.
During his tenure at Telix, Cubbin helped grow the market capitalization of the business to AU$2.3bn (US$1.6bn) and built a global finance team. He was also a key member of the team who successfully completed the Telix IPO, and subsequent capital raises, with a total of AU$270m (US$180m) raised. During his time with Telix, the company made four acquisitions.
Prior to Telix, Cubbin held roles of Chief Financial Officer and Chief Operating Officer at ANSTO, Executive Chairman of ANSTO Nuclear Medicine, and Chief Financial Officer at DHL Oceania and South Pacific.
Cubbin’s appointment follows the recruitment to Vaxxas of Scott Fry as Chief Operating Officer and Daniel Devine as Chief Business Officer and General Counsel.